Orexigen (OREX) Pops Higher on Analyst Upgrade; Volatility Up
Tweet Send to a FriendGet Alerts OREX Hot Sheet
Up)
Trade OREX Now!
Orexigen Therapeutics (Nasdaq: OREX) is ripping higher out of the gate Thursday, following positive late-day news tied to Arena Pharma's (Nasdaq: ARNA) lorcaserin weight-loss drug Wednesday. JPMorgan upgraded the stock to Overweight earlier.
Volatility is up 77.5 percent with shares about 12 percent positive on the session early.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Volatility is up 77.5 percent with shares about 12 percent positive on the session early.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Can AMD (AMD) Shake Off the Goldman Downgrade?
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
- SolarCity (SCTY) is 'Hot, Hot, Hot', But Questions About Financing Deal Raised
Create E-mail Alert Related Categories
Insiders' Blog, Momentum Movers, Options, Trader TalkRelated Entities
JPMorgan
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
